The estimated Net Worth of Yuval Cohen is at least $11 Millón dollars as of 14 June 2024. Mr. Cohen owns over 63,358 units of Corbus Pharmaceuticals Inc stock worth over $4,070,319 and over the last 10 years he sold CRBP stock worth over $2,950,582. In addition, he makes $4,001,510 as Chief Executive Officer y Director at Corbus Pharmaceuticals Inc.
Yuval has made over 32 trades of the Corbus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 63,358 units of CRBP stock worth $2,950,582 on 14 June 2024.
The largest trade he's ever made was selling 63,358 units of Corbus Pharmaceuticals Inc stock on 14 June 2024 worth over $2,950,582. On average, Yuval trades about 4,450 units every 81 days since 2014. As of 14 June 2024 he still owns at least 77,221 units of Corbus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Cohen stock trades at the bottom of the page.
Yuval Cohen serves as Chief Executive Officer, Director of the Company. Dr. Cohen has served as our Chief Executive Officer and as a director since April 11, 2014. Dr. Cohen joined Corbus Pharmaceuticals, Inc. (formerly JB Therapeutics, Inc.), our wholly-owned subsidiary, as its Chief Executive Officer in July 2013. Prior to joining Corbus Pharmaceuticals, Inc., he was the President and co-founder of Celsus Therapeutics PLC (“Celsus”) (Nasdaq CM: CLTX) from 2005 until February 2013, and as Senior Vice President from February 2013 until June 2013. Dr. Cohen was also a board member of Celsus until December 2013. Starting as a small startup with seed financing, under Dr. Cohen’s leadership, Celsus developed five novel anti-inflammatory drug candidates with two reaching Phase IIb stages focusing on allergies and autoimmune diseases of the skin (eczema), airways (cystic fibrosis and hay fever), digestive tract (inflammatory bowel disease) and eye (conjunctivitis). Dr. Cohen participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fundraising. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen holds a BSc (Hons) in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. Dr. Cohen was selected as a director because of his business and leadership experience in the biopharmaceutical sector, as well as a result of having served as a director since our inception.
As the Chief Executive Officer y Director of Corbus Pharmaceuticals Inc, the total compensation of Yuval Cohen at Corbus Pharmaceuticals Inc is $4,001,510. There are no executives at Corbus Pharmaceuticals Inc getting paid more.
Yuval Cohen is 57, he's been the Chief Executive Officer y Director of Corbus Pharmaceuticals Inc since . There are 6 older and 5 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.
Yuval's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.
Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor... y Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: